These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17925883)

  • 21. Chemical leukoderma after the application of a transdermal methylphenidate patch.
    Ghasri P; Gattu S; Saedi N; Ganesan AK
    J Am Acad Dermatol; 2012 Jun; 66(6):e237-8. PubMed ID: 22583724
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
    J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.
    Cortese S; D'Acunto G; Konofal E; Masi G; Vitiello B
    CNS Drugs; 2017 Feb; 31(2):149-160. PubMed ID: 28130762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder.
    Ashkenasi A
    Pediatr Neurol; 2011 Dec; 45(6):381-6. PubMed ID: 22115000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of a methylphenidate transdermal system versus t.i.d. methylphenidate in a laboratory setting.
    Pelham WE; Waxmonsky JG; Schentag J; Ballow CH; Panahon CJ; Gnagy EM; Hoffman MT; Burrows-MacLean L; Meichenbaum DL; Forehand GL; Fabiano GA; Tresco KE; Lopez-Williams A; Coles EK; González MA
    J Atten Disord; 2011 Jan; 15(1):28-35. PubMed ID: 20439487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
    Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ
    Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder.
    Pierce D; Katic A; Buckwalter M; Webster K
    J Clin Psychopharmacol; 2010 Oct; 30(5):554-64. PubMed ID: 20814325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylphenidate transdermal system: in attention-deficit hyperactivity disorder in adolescents.
    Keating GM
    CNS Drugs; 2011 Apr; 25(4):333-42. PubMed ID: 21425884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.
    McBurnett K; Starr HL
    Expert Opin Pharmacother; 2011 Feb; 12(2):315-24. PubMed ID: 21226641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sleep disturbances and ADHD medications.
    Rostain AL
    Curr Psychiatry Rep; 2007 Oct; 9(5):399-400. PubMed ID: 17915079
    [No Abstract]   [Full Text] [Related]  

  • 33. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
    McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
    Yoo HK; Park S; Wang HR; Lee JS; Kim K; Paik KW; Yum MS; Ko TS
    Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.
    Brams M; Mao AR; Doyle RL
    Postgrad Med; 2008 Sep; 120(3):69-88. PubMed ID: 18824827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder.
    Lakić A
    Vojnosanit Pregl; 2012 Feb; 69(2):201-4. PubMed ID: 22500377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Methylphenidate misuse].
    Bruggisser M; Bodmer M; Liechti ME
    Praxis (Bern 1994); 2012 Feb; 101(5):299-305. PubMed ID: 22377977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD.
    Pelham WE; Burrows-Maclean L; Gnagy EM; Fabiano GA; Coles EK; Tresco KE; Chacko A; Wymbs BT; Wienke AL; Walker KS; Hoffman MT
    Exp Clin Psychopharmacol; 2005 May; 13(2):111-26. PubMed ID: 15943544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.